EyePoint's experimental AMD therapy misses bar set by Eylea in late-stage trial
A Phase 3 trial of EyePoint's investigational treatment for wet age-related macular degeneration found it did not perform as well as the established standard of care, Eylea. The disappointing results triggered a sharp decline in the company's stock, which fell 70% at market open. The outcome casts doubt on the drug's potential to challenge the current market leader.
Related stories
Eyepoint's wet AMD therapy misses key endpoint in trial · Drug development
LSD-based treatment shows promise for generalized anxiety disorder in late-stage trial · Mental health
Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “EyePoint’s bid to compete with Eylea falls flat.” Browse more stories.